Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Javaeed, Arslaan; Ghauri, Sanniya Khan; Ibrahim, A.R.; Doheim, Mohamed Fahmy

doi:10.4081/oncol.2020.449

Cited by 5 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36,37 The use of PSA velocity (PSAV) has been proposed and comprehensively reviewed. [38][39][40] In our study, we show that the velocity of change (δ C4 ) of TGF-β1 serum protein along with CD40 and complement component 4 (C4) was different comparing patients with/without MRD at 6 months of treatment. TGF-β1 has been demonstrated to negatively contribute to persistent MRD positive status in several types of cancer.…”

Section: Velocity Profile (δ C4 ) Circumvents Heterogeneity In Protei...mentioning

confidence: 66%

“…The concept of using the velocity of change has been extensively studied, especially for prostate‐specific antigen (PSA), since the most common problem with PSA has been its variable detection, which leads to overdiagnosis and thus, overtreatment 36,37 . The use of PSA velocity (PSAV) has been proposed and comprehensively reviewed 38–40 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

et al. 2021

View full text Add to dashboard Cite

Background: The possibility to monitor patient's serum proteome during treatment can provide deepened understanding of the biology associated with response to specific drugs. Non-invasive serum sampling provides an opportunity for sustainable repetitive sampling of patients, which allows for more frequent evaluation of the biological response and enhanced flexibility in treatment selection in contrast to tissue biopsies. Aim: To pin-point biologically relevant changes in pre-and on-treatment serum proteome samples in relapsed mantle cell lymphoma (MCL) patients, leading to insight into mechanisms behind response to treatment in sub-groups of patients. Methods: Pre-and on-treatment serum samples from relapsed MCL patients treated with a triple combination therapy of rituximab, ibrutinib and lenalidomide were available for the study, together with detailed clinicopathological information. A microarray technology targeting 158 serum proteins using 371 antibody-fragments was used to compare the serum proteome at the two time-points. Results: Proteins modulated by the treatment were shown to be associated to a MCL sub-group with ATM/TP53 alterations, which emphasizes the importance of treatment stratification. Absolute values of serum protein levels in on-treatment samples were highly variable and showed no correlation to outcome. To circumvent the challenge of variability in absolute serum protein levels, the velocity of change of individual serum proteins was used to identify proteins associated with clinical response. Increased values of TGF-β1, CD40 and complement component 4 comparing pre-and on-treatment samples were associated with remaining minimal residual disease (MRD) and increased BTK was associated with short progression-free survival (PFS). Conclusion: We show that the genetic sub-type of MCL affects the biological response to treatment in serum and that the change in defined serum proteins reveals the biology associated with clinical response.

show abstract

Section: Velocity Profile (δ C4 ) Circumvents Heterogeneity In Protei...mentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, a recently published systematic review highlighted that results are conflicting regarding the role of PSAV in predicting progression in patients suitable for active surveillance. Currently, there is no evidence to support the use of PSAV in treatment decision for intermediate-risk PCa [31].…”

Section: Psad and Psa Kineticsmentioning

confidence: 99%

Intermediate-risk Prostate Cancer—A Sheep in Wolf’s Clothing?

Heidegger

Hamdy

Bergh

et al. 2023

European Urology Oncology

View full text Add to dashboard Cite

This case-based discussion describes a 65-year-old man newly diagnosed with International Society of Urological Pathology (ISUP) grade 2 prostate cancer (PCa). According to the European Association of Urology classification system, the patient harbors an intermediate-risk cancer. In step-by step discussion, we elaborate guideline-based treatment modalities for intermediate-risk PCa focused on debating active surveillance versus active treatment. Thereby, we discuss the importance of patient characteristics, including age, hereditary factors, life expectancy and comorbidity status, findings of multiparametric magnetic resonance imaging, as well as prostate-specific antigen (PSA) density and PSA kinetics, in predicting the clinical course of the disease. In addition, we focus on cribriform pathology as a predictor of adverse outcomes and critically discuss its relevance in patient management. Lastly, we outline genomic stratification in ISUP 2 cancer as a future tool to predict PCa aggressiveness. Patient summary: Based on current guidelines, patients with intermediate-risk prostate cancer are treated actively or can alternatively undergo an active surveillance approach when favorable risk factors are present. One major issue is to discriminate between patients who benefit from an active therapy approach and those who benefit from a deferred treatment. Therefore, reliable biomarkers and early predictors of disease progression are needed urgently.

show abstract

“…They concluded that PSAV may act as an early biomarker for the development of PC [ 82 ]. Since this initial study, there has been some debate on the value of PSAV for diagnosing PC or providing a prognosis for PC in patients under AS [ 83 , 84 ]. However, there are studies that indicate that PSAV has potential as a prognostic/predictive biomarker in patients treated with RP [ 85 , 86 , 87 , 88 ] and RT [ 89 , 90 ].…”

Section: Techniques To Improve the Diagnostic Accuracy Of Pcmentioning

confidence: 99%

Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

Meehan

Gray

Martínez-Pérez

et al. 2021

JPM

View full text Add to dashboard Cite

Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is largely based upon clinical signs and the use of prostate-specific antigen (PSA) levels. Although PSA levels have been criticised for a lack of specificity, leading to PC over-diagnosis, it is still the most commonly used biomarker in PC management. Unfortunately, PC is extremely heterogeneous, and it can be difficult to stratify patients whose tumours are unlikely to progress from those that are aggressive and require treatment intensification. Although PC-specific biomarker research has previously focused on disease diagnosis, there is an unmet clinical need for novel prognostic, predictive and treatment response biomarkers that can be used to provide a precision medicine approach to PC management. In particular, the identification of biomarkers at the time of screening/diagnosis that can provide an indication of disease aggressiveness is perhaps the greatest current unmet clinical need in PC management. Largely through advances in genomic and proteomic techniques, exciting pre-clinical and clinical research is continuing to identify potential tissue, blood and urine-based PC-specific biomarkers that may in the future supplement or replace current standard practices. In this review, we describe how PC-specific biomarker research is progressing, including the evolution of PSA-based tests and those novel assays that have gained clinical approval. We also describe alternative diagnostic biomarkers to PSA, in addition to biomarkers that can predict PC aggressiveness and biomarkers that can predict response to certain therapies. We believe that novel biomarker research has the potential to make significant improvements to the clinical management of this disease in the near future.

show abstract

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Cited by 5 publications

References 61 publications

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

Intermediate-risk Prostate Cancer—A Sheep in Wolf’s Clothing?

Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

Contact Info

Product

Resources

About